“I am delighted to welcome Karen to our Board of Directors,” said Stephen Hurly, Chief Executive Officer and President. “She joins us at an exciting time for our company as our first gamma-delta bsTCE candidates progress towards the clinic. Her deep experience leading finance organizations across both clinical- and commercial-stage public life science companies will be invaluable to LAVA as we advance our pipeline aimed at improving patient outcomes and creating value for our shareholders.”
“With two candidates expected to enter the clinic in 2021 following a successful IPO, I am thrilled to join LAVA’s Board,”
About LAVA
LAVA’s Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including in respect of the company’s anticipated growth and clinical developments plans, including the timing of clinical trials. Words such as “anticipate,” “believe,” “could,” “expect,” “should,” “plan,” “intend,” “estimate,” “potential” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on LAVA’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for LAVA’s product candidates, and the potential use of our product candidates to treat various tumor targets. Many factors may cause differences between current expectations and actual results including unexpected safety or efficacy data observed during preclinical trials, changes in expected or existing competition, changes in the regulatory environment, the COVID-19 pandemic may disrupt our business and that of the third parties on which we depend, including delaying or otherwise disrupting our clinical trials and preclinical studies, manufacturing and supply chain, or impairing employee productivity, failure of LAVA’s collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, among others. LAVA assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact
k.zipp@lavatherapeutics.com
Source:
2021 GlobeNewswire, Inc., source